PRAX News and Press, Praxis Precision Medicines Inc. From 11/07/23

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30, 2023 supports runway into ...

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-10-02 14:25:11 ET More on Praxis Precision Medicines Praxis Precision Medicines: Long List Of Failures And Mixed Data Praxis Precision Meds up 9% on new Truist buy rating Larimar, Design higher as they benefit from Biogen deal for Reata Seeking Alpha...

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patie...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

2023-09-19 12:04:29 ET More on Praxis Precision Medicines Praxis Precision Medicines: Long List Of Failures And Mixed Data Larimar, Design higher as they benefit from Biogen deal for Reata Seeking Alpha’s Quant Rating on Praxis Precision Medicines Hist...

2023-09-19 09:35:00 ET A Boston-based %Biotech company is capturing the collective attention of the trading community after it was announced that Truist Securities initiated coverage on the stock, giving it a buy rating and a price target of $10.00/share. Seeing that shares of ...

2023-09-19 08:15:00 ET Gainers: Elutia ( ELUT ) +35% announces sale of Orthobiologics business unit for cash proceeds of Up to $35 Million . CF Acquisition Corp. VIII ( CFFE ) +33% . Avinger ( AVGR ) +32% . on ATM equity offering . Mobilicom...

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...